EirGenix (6589) reported revenue of NT$271.7 million for Oct 2026, +287.9% year on year and +131.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.39 billion (+94.7% year on year).
Revenue for Oct 2026 was a record high (previous high: Nov 2023, NT$256.4 million). →
Year-on-year revenue growth: 6 months in a row. →
In Oct 2026, it ranked No. 36 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$271.7 million | +287.9% | +131.5% |
| Sep 2026 | NT$117.3 million | +43.2% | -28.3% |
| Aug 2026 | NT$163.7 million | +125.9% | -22.7% |
| Jul 2026 | NT$211.8 million | +184.0% | +86.9% |
| Jun 2026 | NT$113.3 million | +94.3% | -3.0% |
| May 2026 | NT$116.8 million | +56.3% | +42.1% |
| Apr 2026 | NT$82.2 million | -15.8% | -28.3% |
| Mar 2026 | NT$114.7 million | +28.2% | +35.0% |
| Feb 2026 | NT$85 million | +100.6% | -21.9% |
| Jan 2026 | NT$108.8 million | +117.1% | -31.1% |
| Dec 2025 | NT$157.8 million | +14.0% | +16.2% |
| Nov 2025 | NT$135.8 million | +41.6% | +93.9% |
| Oct 2025 | NT$70 million | +16.1% | -14.5% |
| Sep 2025 | NT$82 million | +4.8% | +13.1% |
| Aug 2025 | NT$72.5 million | -11.1% | -2.9% |
| Jul 2025 | NT$74.6 million | -15.8% | +27.9% |
| Jun 2025 | NT$58.3 million | -4.2% | -21.9% |
| May 2025 | NT$74.7 million | -37.9% | -23.5% |
| Apr 2025 | NT$97.6 million | +49.8% | +9.1% |
| Mar 2025 | NT$89.5 million | +53.1% | +111.3% |
| Feb 2025 | NT$42.3 million | -10.2% | -15.5% |
| Jan 2025 | NT$50.1 million | -56.1% | -63.8% |
| Dec 2024 | NT$138.4 million | +30.3% | +44.3% |
| Nov 2024 | NT$95.9 million | -62.6% | +59.0% |
| Oct 2024 | NT$60.3 million | -35.8% | -22.9% |
Jan–Oct 2026 cumulative: NT$1.39 billion (+94.7% YoY)
Other Biotech & Medical companies
Compare with peers: EirGenix vs PEC / EirGenix vs Lotus Pharm / EirGenix vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月:EG1206A達成里程碑依完工比例認列授權收入及CDMO業務成長。本年:自有產品授權金逐步認列及CDMO業務成長。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16